{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:34:28Z","timestamp":1790091268798,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacepopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACEP Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.acepjo.2026.100337","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T20:14:20Z","timestamp":1771532060000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-5692","authenticated-orcid":false,"given":"Jace C.","family":"Bradshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laeben","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.acepjo.2026.100337_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jpain.2006.12.005","article-title":"Pain in the emergency department: results of the Pain and Emergency Medicine Initiative (PEMI) multicenter study","volume":"8","author":"Todd","year":"2007","journal-title":"J Pain"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajem.2014.01.015","article-title":"Prevalence and treatment of pain in EDs in the United States, 2000 to 2010","volume":"32","author":"Chang","year":"2014","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.acepjo.2026.100337_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ajem.2002.32643","article-title":"The high prevalence of pain in emergency medical care","volume":"20","author":"Cordell","year":"2002","journal-title":"Am J Emerg Med"},{"issue":"6","key":"10.1016\/j.acepjo.2026.100337_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jemermed.2020.07.016","article-title":"Predicting the transition to chronic pain 6 months after an emergency department visit for acute pain: a prospective cohort study","volume":"59","author":"Friedman","year":"2020","journal-title":"J Emerg Med"},{"key":"10.1016\/j.acepjo.2026.100337_bib5","series-title":"Policy statement: optimizing the treatment of acute pain in the emergency department","year":"2017"},{"issue":"13","key":"10.1016\/j.acepjo.2026.100337_bib6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.2011.401","article-title":"Characteristics of opioid prescriptions in 2009","volume":"305","author":"Volkow","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2007.64","article-title":"Trends in opioid prescribing by race\/ethnicity for patients seeking care in US emergency departments","volume":"299","author":"Pletcher","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.acepjo.2026.100337_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1186\/s12889-025-22210-8","article-title":"Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis","volume":"25","author":"Fischer","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.acepjo.2026.100337_bib10","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6734a2","article-title":"Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016\u2013June 2017","volume":"67","author":"Mattson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.annemergmed.2014.06.016","article-title":"The opioid prescription epidemic and the role of emergency medicine","volume":"64","author":"Poon","year":"2014","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.acepjo.2026.100337_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-025-02178-w","article-title":"Suzetrigine: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.acepjo.2026.100337_bib13","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/JPR.S527710","article-title":"Suzetrigine: is this what we have been waiting for or just the beginning?","volume":"18","author":"Robinson","year":"2025","journal-title":"J Pain Res"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib14","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1213\/ANE.0000000000007550","article-title":"US Food and Drug Administration Approval of suzetrigine: a breakthrough in nonopioid pain management","volume":"141","author":"Ul Haq","year":"2025","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresrev.2008.12.005","article-title":"Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment","volume":"60","author":"Dib-Hajj","year":"2009","journal-title":"Brain Res Rev"},{"issue":"7121","key":"10.1016\/j.acepjo.2026.100337_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.acepjo.2026.100337_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJMe2305708","article-title":"Targeting a peripheral sodium channel to treat pain","volume":"389","author":"Waxman","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.acepjo.2026.100337_bib19","first-page":"1085","article-title":"Suzetrigine, a nonopioid NaV1. 8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1. 8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acepjo.2026.100337_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"issue":"2","key":"10.1016\/j.acepjo.2026.100337_bib22","article-title":"Suzetrigine drug-drug interactions: perioperative anesthesia considerations to enhance patient safety","volume":"40","author":"McCoy","year":"2025","journal-title":"APSF Newsletter"},{"issue":"3","key":"10.1016\/j.acepjo.2026.100337_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/138920009787846305","article-title":"Polymorphic drug metabolism in anaesthesia","volume":"10","author":"Restrepo","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.acepjo.2026.100337_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2023.153682","article-title":"The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine","volume":"500","author":"Li","year":"2023","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.acepjo.2026.100337_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5507\/bp.2022.019","article-title":"The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress","volume":"166","author":"Zemanova","year":"2022","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2710.1999.00247.x","article-title":"Clinically significant pharmacokinetic drug interactions with benzodiazepines","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.acepjo.2026.100337_bib27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0090-9556(25)07486-0","article-title":"Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4","volume":"24","author":"Feierman","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.acepjo.2026.100337_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2165\/00003088-199631030-00002","article-title":"Clinical pharmacokinetics of rocuronium bromide","volume":"31","author":"Khuenl-Brady","year":"1996","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.acepjo.2026.100337_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jphs.2014.12.006","article-title":"Interaction of rocuronium with human liver cytochromes P450","volume":"127","author":"Anzenbacherova","year":"2015","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.acepjo.2026.100337_bib30","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1213\/00000539-199806000-00036","article-title":"The pharmacokinetics of vecuronium in male and female patients","volume":"86","author":"Xue","year":"1998","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-3565(25)12795-X","article-title":"Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation","volume":"277","author":"Gentile","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.acepjo.2026.100337_bib32","first-page":"457","article-title":"Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo","volume":"57","author":"Villikka","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-200443010-00002","article-title":"Pharmacokinetics of local anaesthetics in infants and children","volume":"43","author":"Mazoit","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.acepjo.2026.100337_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.acepjo.2026.100337_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03190040","article-title":"Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4","volume":"24","author":"Kelly","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.acepjo.2026.100337_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187231210790980408","article-title":"An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6","volume":"4","author":"Lewis","year":"2010","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.acepjo.2026.100337_bib39","series-title":"Highlights of prescribing information. JOURNAVXTM (suzetrigine) tablets","year":"2025"},{"issue":"8","key":"10.1016\/j.acepjo.2026.100337_bib40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/acem.13628","article-title":"Opioid use and misuse three months after emergency department visit for acute pain","volume":"26","author":"Daoust","year":"2019","journal-title":"Acad Emerg Med"}],"container-title":["JACEP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115226000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115226000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:19:28Z","timestamp":1775247568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2688115226000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2688115226000123"],"URL":"https:\/\/doi.org\/10.1016\/j.acepjo.2026.100337","relation":{},"ISSN":["2688-1152"],"issn-type":[{"value":"2688-1152","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker","name":"articletitle","label":"Article Title"},{"value":"JACEP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acepjo.2026.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American College of Emergency Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}